46
Participants
Start Date
December 31, 2006
Primary Completion Date
January 31, 2009
Study Completion Date
January 31, 2009
SGN-40
1-8 mg/kg IV (in the vein) on Days 1, 4, 8, 15, 22 and 29 of Cycle 1; 8 mg/kg IV (in the vein) on Days 1, 8, 15, and 22 for Cycles 2-12.
Weill Medical College of Cornell University, New York
Georgetown University, Washington D.C.
Charleston Hematology Oncology Associates, PA, Charleston
University of Alabama at Birmingham, Birmingham
University of Wisconsin, Madison
Mayo Clinic-Rochester, Rochester
Northwestern University, Chicago
Rush University Medical Center, Chicago
Washington University School of Medicine, St Louis
Mayo Clinic-Arizona, Scottsdale
University of California Los Angeles, Los Angeles
Sharp Healthcare, San Diego
Stanford University Medical Center, Palo Alto
Swedish Cancer Institute, Seattle
Collaborators (1)
Genentech, Inc.
INDUSTRY
Seagen Inc.
INDUSTRY